Genesee Valley Trust Co buys $1,534,851 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Genesee Valley Trust Co scooped up 670 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 26,192 shares of Merck & Co. which is valued at $1,534,851.Merck & Co. makes up approximately 1.00% of Genesee Valley Trust Co’s portfolio.

Other Hedge Funds, Including , Umb Bank N Amo boosted its stake in MRK in the latest quarter, The investment management firm added 9,434 additional shares and now holds a total of 316,408 shares of Merck & Co. which is valued at $18,541,509. Merck & Co. makes up approx 0.76% of Umb Bank N Amo’s portfolio.United Bank Va boosted its stake in MRK in the latest quarter, The investment management firm added 2,790 additional shares and now holds a total of 64,957 shares of Merck & Co. which is valued at $3,806,480. Merck & Co. makes up approx 3.59% of United Bank Va’s portfolio.Legacy Private Trust boosted its stake in MRK in the latest quarter, The investment management firm added 618 additional shares and now holds a total of 12,894 shares of Merck & Co. which is valued at $761,004. Merck & Co. makes up approx 0.11% of Legacy Private Trust’s portfolio.Stillwater Investment Management boosted its stake in MRK in the latest quarter, The investment management firm added 46 additional shares and now holds a total of 5,603 shares of Merck & Co. which is valued at $332,538. Merck & Co. makes up approx 0.19% of Stillwater Investment Management’s portfolio.

Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.